芩珠凉血合剂治疗血热证银屑病的随机对照临床研究.doc苓珠凉血合剂治疗血热证银屑病的随机对照临床研究作者:作者:李福伦,李斌,徐蓉,宋勋,余杨,许铮城【摘要】观察苓珠凉血合剂治疗血热证银屑病的临床疗效并探讨其部分作用机制。方法:58例辨证为血热证的寻常型银屑病患者,随机分为苓珠凉血合剂治疗组和西药复方氨肽素对照组,分别了以4周药物治疗。检测两组患者的血管内皮生长凶子(vascularendothelialgrowthfactor,VEGF)水平变化,问卷调查患者皮肤病生活质量(DermatologyLifeQualityIndex,DLQI)的差异,并采用银屑病而积严重程度指数(PsoriasisAreaandSeverityIndex,PASI)评分法观察临床疗效。结果:%,%,两组比鮫,差异有统计学意义(P<)o两组患者DLQI评分在用药2周及用药4周后均下降(P<);(P<),而对照组用药前后VEGF水平差界无统计学意义(P>),两组治疗后VEGF水平比较,差异有统计学意义(P<)。结论:苓珠凉血合剂能明显改善患者皮损状况和生活质量,其机制可能与卞调患者血清VEGF水平,拮抗血管新生有关。【关键词】血热;银屑病;临床研究Objective:ToexploretheclinicalefficacyofQinzhuLiangxueDecoction(QZLXD),acompoundtraditionalChineseherbalmedicine,:Fiftyeightpatientsdiagnosedwithbloodheattypepsoriasisvulgariswererandomlydividedintotwogroups:QZLXDgroup(30cases)andampeptidegroup(28cases).(PASI)score,DermatologyLifeQualityIndex(DLQI)scoreandthelevelofserumvascularendothelialgrowthfactor(VEGF):TherewasabettercurativeresultinQZLXDgroupthaninampeptidegroup(P<).%%(P<).TherewasnosignificantdifferenceinVEGFlevelbe
芩珠凉血合剂治疗血热证银屑病的随机对照临床研究 来自淘豆网www.taodocs.com转载请标明出处.